|
nasdaq:tnxp
|
2339036
|
Apr 28th, 2024 12:00AM
|
Tonix Pharmaceuticals
|
10K
|
107.00
|
Open
|
|
Apr 28th, 2024 12:06AM
|
Apr 28th, 2024 12:06AM
|
Tonix is a biopharmaceutical company, publicly traded on NASDAQ (ticker: TNXP). The Company is focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. The Company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, which also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.
|
Open
|
|
Open
|
26 Main St
|
Chatham
|
New Jersey
|
US
|
07928
|
|
Tonix Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tnxp
|
2339036
|
Apr 27th, 2024 12:00AM
|
Tonix Pharmaceuticals
|
10K
|
107.00
|
Open
|
|
Apr 26th, 2024 11:45PM
|
Apr 26th, 2024 11:45PM
|
Tonix is a biopharmaceutical company, publicly traded on NASDAQ (ticker: TNXP). The Company is focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. The Company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, which also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.
|
Open
|
|
Open
|
26 Main St
|
Chatham
|
New Jersey
|
US
|
07928
|
|
Tonix Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tnxp
|
2339036
|
Apr 26th, 2024 12:00AM
|
Tonix Pharmaceuticals
|
10K
|
107.00
|
Open
|
|
Apr 25th, 2024 11:52PM
|
Apr 26th, 2024 09:13AM
|
Tonix is a biopharmaceutical company, publicly traded on NASDAQ (ticker: TNXP). The Company is focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. The Company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, which also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.
|
Open
|
|
Open
|
26 Main St
|
Chatham
|
New Jersey
|
US
|
07928
|
|
Tonix Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tnxp
|
2339036
|
Apr 25th, 2024 12:00AM
|
Tonix Pharmaceuticals
|
10K
|
107.00
|
Open
|
|
Apr 24th, 2024 11:47PM
|
Apr 25th, 2024 07:26PM
|
Tonix is a biopharmaceutical company, publicly traded on NASDAQ (ticker: TNXP). The Company is focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. The Company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, which also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.
|
Open
|
|
Open
|
26 Main St
|
Chatham
|
New Jersey
|
US
|
07928
|
|
Tonix Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tnxp
|
2339036
|
Apr 24th, 2024 12:00AM
|
Tonix Pharmaceuticals
|
10K
|
106.00
|
Open
|
|
Apr 23rd, 2024 11:55PM
|
Apr 24th, 2024 11:55AM
|
Tonix is a biopharmaceutical company, publicly traded on NASDAQ (ticker: TNXP). The Company is focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. The Company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, which also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.
|
Open
|
|
Open
|
26 Main St
|
Chatham
|
New Jersey
|
US
|
07928
|
|
Tonix Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tnxp
|
2339036
|
Apr 23rd, 2024 12:00AM
|
Tonix Pharmaceuticals
|
10K
|
107.00
|
Open
|
|
Apr 22nd, 2024 11:36PM
|
Apr 22nd, 2024 11:36PM
|
Tonix is a biopharmaceutical company, publicly traded on NASDAQ (ticker: TNXP). The Company is focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. The Company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, which also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.
|
Open
|
|
Open
|
26 Main St
|
Chatham
|
New Jersey
|
US
|
07928
|
|
Tonix Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tnxp
|
2339036
|
Apr 22nd, 2024 12:00AM
|
Tonix Pharmaceuticals
|
10K
|
107.00
|
Open
|
|
Apr 22nd, 2024 12:31AM
|
Apr 22nd, 2024 12:31AM
|
Tonix is a biopharmaceutical company, publicly traded on NASDAQ (ticker: TNXP). The Company is focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. The Company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, which also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.
|
Open
|
|
Open
|
26 Main St
|
Chatham
|
New Jersey
|
US
|
07928
|
|
Tonix Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tnxp
|
2339036
|
Apr 21st, 2024 12:00AM
|
Tonix Pharmaceuticals
|
10K
|
109.00
|
Open
|
|
Apr 21st, 2024 03:21AM
|
Apr 21st, 2024 03:21AM
|
Tonix is a biopharmaceutical company, publicly traded on NASDAQ (ticker: TNXP). The Company is focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. The Company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, which also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.
|
Open
|
|
Open
|
26 Main St
|
Chatham
|
New Jersey
|
US
|
07928
|
|
Tonix Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tnxp
|
2339036
|
Apr 20th, 2024 12:00AM
|
Tonix Pharmaceuticals
|
10K
|
108.00
|
Open
|
|
Apr 20th, 2024 12:13AM
|
Apr 20th, 2024 05:44PM
|
Tonix is a biopharmaceutical company, publicly traded on NASDAQ (ticker: TNXP). The Company is focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. The Company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, which also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.
|
Open
|
|
Open
|
26 Main St
|
Chatham
|
New Jersey
|
US
|
07928
|
|
Tonix Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:tnxp
|
2339036
|
Apr 19th, 2024 12:00AM
|
Tonix Pharmaceuticals
|
10K
|
108.00
|
Open
|
|
Apr 19th, 2024 04:44AM
|
Apr 19th, 2024 04:44AM
|
Tonix is a biopharmaceutical company, publicly traded on NASDAQ (ticker: TNXP). The Company is focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. The Company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, which also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.
|
Open
|
|
Open
|
26 Main St
|
Chatham
|
New Jersey
|
US
|
07928
|
|
Tonix Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|